KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study.

Miguel Regueiro, Monika Fischer, Peter Bossuyt, Marijana Protic, Kristina Traxler, Guanglei Yu, Huaiyu Zang, Aisha Vadhariya, Tadakazu Hisamatsu, Pascal Juillerat, Alessandro Armuzzi, Javier P Gisbert, Alissa Walsh

J Crohns Colitis 19(7) jjaf100

PMID40491246
PMCIDPMC12231548
DOI10.1093/ecco-jcc/jjaf100
发表日期2025-06-10
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:森林图/亚组分析图;Figure 3:生活质量量表图;Figure 4:AI 判定为 other。
摘要

摘要

BACKGROUND: Fatigue is a debilitating multifactorial symptom experienced by patients with Crohn's disease (CD). Mirikizumab, an anti-interleukin-23p19 antibody, demonstrated significant efficacy and safety in the patients with moderately to severely active CD. This analysis investigated the impact of mirikizumab on fatigue and the association between changes in clinical, endoscopic, and patient-reported outcomes with improvement in fatigue from baseline in the Phase 3 VIVID-1 study. METHODS: Adult patients with moderately to severely active CD that failed at least 1 biologic agent or conventional therapy were randomized to receive mirikizumab or placebo. Fatigue was assessed via the validated Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire. Fatigue associations with patient-reported outcomes, endoscopic, and clinical measures were assessed via Pearson correlation analysis. RESULTS: At Week 12, 43% and 33%, and at Week 52, 46% and 36% of mirikizumab-treated patients achieved ≥ 6 and ≥ 9 fatigue score improvements vs placebo (Week 12, 31%, 22%; Week 52, 20%, 16%), respectively. Baseline fatigue scores were strongly associated with depressive symptoms and moderately associated with quality of life (QoL) at baseline. Improvements in fatigue at Weeks 12 and 52 were strongly associated with QoL and patient-reported outcomes and weakly with objective markers of inflammation and disease activity. CONCLUSIONS: Mirikizumab-treated patients with CD achieved higher rates of clinically meaningful improvement in fatigue vs placebo at Weeks 12 and 52, which correlated with improvement in clinical and patient-reported outcomes. Baseline fatigue severity was strongly associated with depressive symptoms in VIVID-1 (NCT03926130).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. FACIT-Fatigue score assessment in patients randomized to mirikizumab and placebo. (A) Data are LSM (95% CI), and comparisons were performed using ANCOVA with mBOCF. For patients in the placebo group who switched to mirikizumab at Week 12, baseline values were carried forward to derive the change from baseline at Week 52. (B-C) Data are (%) unless otherwise stated. Comparisons were performed using Cochran-Mantel-Haenszel test. a ≥ 30% decrease in SF or AP, and neither worse than baseline. ANCOVA, analysis of covariance; AP, abdominal pain; FACIT, Functional Assessment of Chronic Illness Therapy; mBOCF, modified baseline observation carried forward; PRO, Patient-Reported Outcome; SF, stool frequency.
非 KM Figure
Figure 2Figure 2. Baseline FACIT-Fatigue scores association analysis for patients randomized to mirikizumab and placebo. Random forest regression model was applied to rank variables by importance associated with FACIT-F scores at baseline. Variable importance was measured by the percentage increase in mean squared error (ie, %IncMSE) after permuting a specific predictor in the random forest model; higher percentages indicate greater importance. *Data for fecal calprotectin and C-reactive protein are log-transformed. CDAI=Crohn’s Disease Activity Index; CRP=C-reactive protein; DSI-CD, Disease Severity Index-Crohn’s Disease; IBDQ, Inflammatory Bowel Disease Questionnaire; IBD-DI, Inflammatory Bowel Disease-Disability Index; Miri, mirikizumab; NRS, numeric rating scale; PGRS, Patient Global Rating of Severity; SES-CD, Simple Endoscopic Score for Crohn’s Disease.
非 KM Figure
Figure 3Figure 3. Correlation of change from baseline in FACIT-Fatigue with change from baseline in clinical and quality of life outcomes at Week 12 (A) and Week 52 (B). The absolute value of Pearson correlation is 0.10-0.30 as weak, > 0.30-0.50 as moderate, and > 0.50 to 1 as strong. Pearson correlation is plotted with 95% confidence interval limits. NRS, numeric rating scale; CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; Hb, Hemoglobin; HCT, Hematocrit; IBDQ, Inflammatory Bowel Disease Questionnaire; MCS, mental component summary score; PCS, physical component summary score; QIDS, Quick Inventory of Depressive Symptomatology; RHI, Robarts Histopathology Index(Total Colon); SES-CD, Simple Endoscopic Score for Crohn’s Disease.
非 KM Figure
Figure 4Figure 4. Ranking predictor importance with FACIT-Fatigue scores at Weeks 12 (A, B) and 52 (C, D). Ranking of predictor importance, measured by Wald chi-square value minus the degree of freedom (df) of the predictor, based on multivariable logistic regression. X-axis is represented as “Chi-squared minus degrees of freedom,” which indicates the strength of the predictor variable’s impact on the outcome and its explanatory power in the model. A larger value of Wald chi-square minus df indicates a higher importance of the predictor, meaning it provides more explanatory power to the model. Corresponding P -values < .05 indicate that the predictor variable contributes significantly to model.
非 KM Figure